

Dengue — Continued

Editorial Note: Dengue type 4 frequently occurs in Southeast Asia, the South Pacific, and Africa. How it was introduced onto St. Barthelemy, a small and relatively remote island in the Caribbean, remains unknown. However, French health authorities have reported to CAREC that an outbreak of dengue-like illness has been observed on St. Barthelemy, beginning in February or March, but has since declined. In the absence of reports of an ongoing outbreak of dengue in the Caribbean, the risk that travelers to this area will acquire dengue is probably small.

Dengue types 2 and 3 have been present in the Caribbean at least since the 1960s. Dengue type 1 was first recognized in that area when an outbreak in Jamaica in 1977 was followed by numerous outbreaks on other Caribbean islands and in Central America. All these dengue types, as well as type 4, usually cause an illness that is clinically mild and typically of short duration.

Pneumocystis Pneumonia — Los Angeles

In the period October 1980-May 1981, 5 young men, all active homosexuals, were treated for biopsy-confirmed *Pneumocystis carinii* pneumonia at 3 different hospitals in Los Angeles, California. Two of the patients died. All 5 patients had laboratory-confirmed previous or current cytomegalovirus (CMV) infection and candidal mucosal infection. Case reports of these patients follow.

Patient 1: A previously healthy 33-year-old man developed *P. carinii* pneumonia and oral mucosal candidiasis in March 1981 after a 2-month history of fever associated with elevated liver enzymes, leukopenia, and CMV viruria. The serum complement-fixation CMV titer in October 1980 was 256; in May 1981 it was 32.* The patient's condition deteriorated despite courses of treatment with trimethoprim-sulfamethoxazole (TMP/SMX), pentamidine, and acyclovir. He died May 3, and postmortem examination showed residual *P. carinii* and CMV pneumonia, but no evidence of neoplasia.

Patient 2: A previously healthy 30-year-old man developed *P. carinii* pneumonia in April 1981 after a 5-month history of fever each day and of elevated liver-function tests, CMV viruria, and documented seroconversion to CMV, i.e., an acute-phase titer of 16 and a convalescent-phase titer of 28* in anticomplement immunofluorescence tests. Other features of his illness included leukopenia and mucosal candidiasis. His pneumonia responded to a course of intravenous TMP/SMX, but, as of the latest reports, he continues to have a fever each day.

Patient 3: A 30-year-old man was well until January 1981 when he developed esophageal and oral candidiasis that responded to Amphotericin B treatment. He was hospitalized in February 1981 for *P. carinii* pneumonia that responded to oral TMP/SMX. His esophageal candidiasis recurred after the pneumonia was diagnosed, and he was again given Amphotericin B. The CMV complement-fixation titer in March 1981 was 8. Material from an esophageal biopsy was positive for CMV.

Patient 4: A 29-year-old man developed *P. carinii* pneumonia in February 1981. He had had Hodgkins disease 3 years earlier, but had been successfully treated with radiation therapy alone. He did not improve after being given intravenous TMP/SMX and corticosteroids and died in March. Postmortem examination showed no evidence of Hodgkins disease, but *P. carinii* and CMV were found in lung tissue.

*Paired specimens not run in parallel.

Pneumonia – Continued

Patient 5: A previously healthy 36-year-old man with a clinically diagnosed CMV infection in September 1980 was seen in April 1981 because of a 4-month history of fever, dyspnea, and cough. On admission he was found to have *P. carinii* pneumonia, oral candidiasis, and CMV retinitis. A complement-fixation CMV titer in April 1981 was 128. The patient has been treated with 2 short courses of TMP/SMX that have been limited because of a sulfa-induced neutropenia. He is being treated for candidiasis with topical nystatin.

The diagnosis of *Pneumocystis* pneumonia was confirmed for all 5 patients ante-mortem by closed or open lung biopsy. The patients did not know each other and had no known common contacts or knowledge of sexual partners who had similar illnesses. The 5 did not have comparable histories of sexually transmitted disease. Four had serologic evidence of past hepatitis B infection but had no evidence of current hepatitis B surface antigen. Two of the 5 reported having frequent homosexual contacts with various partners. All 5 reported using inhalant drugs, and 1 reported parenteral drug abuse. Three patients had profoundly depressed numbers of thymus-dependent lymphocyte cells and profoundly depressed *in vitro* proliferative responses to mitogens and antigens. Lymphocyte studies were not performed on the other 2 patients.

Reported by MS Gottlieb, MD, HM Schanker, MD, PT Fan, MD, A Saxon, MD, JD Weisman, DO, Div of Clinical Immunology-Allergy, Dept of Medicine, UCLA School of Medicine; I Pozalski, MD, Cedars-Mt. Sinai Hospital, Los Angeles; Field Services Div, Epidemiology Program Office, CDC.

Editorial Note: *Pneumocystis* pneumonia in the United States is almost exclusively limited to severely immunosuppressed patients (1). The occurrence of pneumocystosis in these 5 previously healthy individuals without a clinically apparent underlying immunodeficiency is unusual. The fact that these patients were all homosexuals suggests an association between some aspect of a homosexual lifestyle or disease acquired through sexual contact and *Pneumocystis* pneumonia in this population. All 5 patients described in this report had laboratory-confirmed CMV disease or virus shedding within 5 months of the diagnosis of *Pneumocystis* pneumonia. CMV infection has been shown to induce transient abnormalities of *in vitro* cellular-immune function in otherwise healthy human hosts (2,3). Although all 3 patients tested had abnormal cellular-immune function, no definitive conclusion regarding the role of CMV infection in these 5 cases can be reached because of the lack of published data on cellular-immune function in healthy homosexual males with and without CMV antibody. In 1 report, 7 (3.6%) of 194 patients with pneumocystosis also had CMV infection; 40 (21%) of the same group had at least 1 other major concurrent infection (1). A high prevalence of CMV infections among homosexual males was recently reported: 179 (94%) of 190 males reported to be exclusively homosexual had serum antibody to CMV, and 14 (7.4%) had CMV viruria; rates for 101 controls of similar age who were reported to be exclusively heterosexual were 54% for seropositivity and zero for viruria (4). In another study of 64 males, 4 (6.3%) had positive tests for CMV in semen, but none had CMV recovered from urine. Two of the 4 reported recent homosexual contacts. These findings suggest not only that virus shedding may be more readily detected in seminal fluid than in urine, but also that seminal fluid may be an important vehicle of CMV transmission (5).

All the above observations suggest the possibility of a cellular-immune dysfunction related to a common exposure that predisposes individuals to opportunistic infections such as pneumocystosis and candidiasis. Although the role of CMV infection in the pathogenesis of pneumocystosis remains unknown, the possibility of *P. carinii* infection must be carefully considered in a differential diagnosis for previously healthy homosexual males with dyspnea and pneumonia.

*Pneumonia – Continued**References*

1. Walzer PD, Perl DP, Krogstad DJ, Rawson PG, Schultz MG. *Pneumocystis carinii* pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. *Ann Intern Med* 1974; 80:83-93.
2. Rinaldo CR, Jr, Black PH, Hirsch MS. Interaction of cytomegalovirus with leukocytes from patients with mononucleosis due to cytomegalovirus. *J Infect Dis* 1977;136:667-78.
3. Rinaldo CR, Jr, Carney WP, Richter BS, Black PH, Hirsch MS. Mechanisms of immunosuppression in cytomegaloviral mononucleosis. *J Infect Dis* 1980;141:488-95.
4. Drew WL, Mintz L, Miner RC, Sands M, Ketterer B. Prevalence of cytomegalovirus infection in homosexual men. *J Infect Dis* 1981;143:188-92.
5. Lang DJ, Kummer JF. Cytomegalovirus in semen: observations in selected populations. *J Infect Dis* 1975;132:472-3.

*Current Trends***Measles – United States, First 20 Weeks**

During the first 20 weeks (through May 23) of 1981, a total of 1,532 cases of measles were reported in the United States (Table 1). This represents an 82% decrease from the 8,519 cases reported during this same period in 1980. If this trend continued throughout the year, fewer than 2,500 cases would be reported in 1981. The previous record low incidence for an entire calendar year was 13,430 cases (provisional total) reported in 1980.

TABLE 1. Measles – United States, May 23, 1981

Year	Week 20	Weeks 1-20
1981	135	1,532
1980	816	8,519
1970	1,950	27,955
1960	18,833	286,097

More than 100 measles cases have been reported each week since week 17 (May 2), ending 37 consecutive weeks during which fewer than 100 cases per week were reported. Nevertheless, the number of cases reported in the last 4 weeks are still record lows. The seasonal upswing in reported cases, which usually occurs in late winter and spring, has not yet occurred (Figure 1).

Seventeen states have not reported any measles cases in 1981. In contrast, only 5 states did not report any measles cases for the same period in 1980.

Reported by Surveillance and Assessment Br, Immunization Div, Center for Prevention Services, CDC.

Editorial Note: The reported incidence of measles in 1981 continues at record low levels, indicating that measles transmission has been interrupted in most areas of the United States. The goal of elimination of indigenous measles from the United States by October 1, 1982, is within reach, provided intensive control efforts are continued.